Plexision performs custom R&D projects aimed at integrating biomarker targets in all phases of drug development, from preclinical to post-marketing.

A range of antigen-specific and non-specific cell-based assays can be adapted for immunological drug development services in the following categories:

• Predicting effective concentrations of single and multiple-drug regimens.
• Design and development of cell-based companion diagnostics.
• Surrogate endpoint development.
• Assay validation and performance assessment.

Assay and support capabilities include:

• Pathogen and mitogen-specific immune responses.
• Antiviral (cellular) immunity.
• T- and B-cell subset sensitivity to drugs and apoptosis.
• Antigen presentation.
• Cryopreservation
• Contract research.
• GLP and GMP-compliance.

Plexision can also assist drug developers in regulatory submissions for biomarker qualification.

If you would like to know more about our research capabilities, please contact us at info@plexision.com.